LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

Vision, clarity and enabling – the drivers for Europe’s biomanufacturing future

16/03/2023
PRESS RELEASE

Brussels, 16 March 2023 – Visionary policy, urgency, a clear voice from industry, and enabling regulation for biomanufacturing were the key takeaways from EuropaBio’s first Biomanufacturing Policy Summit, hosted on March 15 in Brussels.

Over 75 EuropaBio members and guests from across the biomanufacturing spectrum came together to discuss Europe in global terms – how to make the most of its advantages and address the critical points that slow its progress compared to other parts of the world.

The meeting kick-started by setting the scene – Europe’s ambition, led by RTD’s Peter Dröll, followed by a look inside the White House Executive Order with BIO’s Hilary Stiss and biopharma manufacturing as a measure of Europe’s competitiveness, with Wojciech Nowak of Novartis. ‘I am Biomanufacturing’ saw three faces of biomanufacturing, with Evonik’s walk through the everyday products in our life that are the changing origins of chemicals, SwiftPharma moving the needle on plant-manufactured drugs, and Belgium showing how it’s done in building the ecosystem for success.

Delegates got to work debating where Europe should be in 10 years for biomanufacturing, why it’s important, and what are the incentives and obstacles on the way. The afternoon wrapped with a panel discussion moderated by GROW’s Kristin Schreiber, with panelists Peter Wehrheim of RTD, Kristin Thompson of investor EUREKARE, Nessa Fennelly of Ireland’s Ibec, Nicolo Giacomuzzi-Moore of CBE JU and Stefaan Fiers of Takeda Belgium. A level playing field for the much-needed transition to sustainably produced products was a key point plus the need for serious communication with consumers and investment into the skills to deliver. Finally, the day closed with the question to all on whether Europe wants to be the pilot or the passenger on the world’s transition into a biomanufacturing powerhouse, a message that EuropaBio takes into its vision for Biomanufacturing Platform delivery over the coming year.

Claire Skentelbery, EuropaBio DG commented “Yesterday saw a first step in the recognition of the value and impact of biomanufacturing and Europe’s essential journey for industrial transformation. The diversity of delegates showed the role for multiple actors, united by their ambition for what Europe can achieve.”

Vision, clarity and enabling – the drivers for Europe’s biomanufacturing future


Download
Share
Communications Team
Communications Team

Related posts

14/11/2025

Vial joins EuropaBio: Reimagining Drug Development with Hyper-Scalable Biotech


Read more
12/11/2025

EuropaBio response to the EU Biotech Act public consultation


Read more
31/10/2025

Healthcare Associations warn of risks from PFAS restriction approach  – failure to assess the impact on the availability of human and animal medicines


Read more

Important links

  • Vial joins EuropaBio: Reimagining Drug Development with Hyper-Scalable Biotech
  • EuropaBio response to the EU Biotech Act public consultation

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.